A detailed history of Alps Advisors Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 54,969 shares of CRNX stock, worth $2.46 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
54,969
Previous 46,025 19.43%
Holding current value
$2.46 Million
Previous $1.64 Million 57.18%
% of portfolio
0.02%
Previous 0.01%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$34.76 - $46.81 $310,893 - $418,668
8,944 Added 19.43%
54,969 $2.57 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $145,957 - $211,187
5,697 Added 14.13%
46,025 $1.64 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $9,869 - $18,904
618 Added 1.56%
40,328 $1.2 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $65,908 - $98,884
4,190 Added 11.8%
39,710 $715,000
Q1 2023

May 10, 2023

SELL
$15.31 - $21.1 $14,651 - $20,192
-957 Reduced 2.62%
35,520 $570,000
Q4 2022

Feb 14, 2023

BUY
$15.49 - $19.05 $110,768 - $136,226
7,151 Added 24.38%
36,477 $667,000
Q3 2022

Nov 14, 2022

SELL
$18.11 - $22.37 $43,717 - $54,001
-2,414 Reduced 7.61%
29,326 $576,000
Q2 2022

Aug 11, 2022

SELL
$16.49 - $27.64 $281,566 - $471,953
-17,075 Reduced 34.98%
31,740 $592,000
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $105,455 - $174,078
-6,149 Reduced 11.19%
48,815 $1.07 Million
Q4 2021

Feb 09, 2022

BUY
$19.35 - $28.41 $145,666 - $213,870
7,528 Added 15.87%
54,964 $1.56 Million
Q3 2021

Nov 15, 2021

SELL
$16.88 - $25.23 $35,110 - $52,478
-2,080 Reduced 4.2%
47,436 $999,000
Q2 2021

Aug 11, 2021

SELL
$15.9 - $21.15 $159,747 - $212,494
-10,047 Reduced 16.87%
49,516 $933,000
Q1 2021

May 07, 2021

BUY
$13.3 - $17.55 $1,675 - $2,211
126 Added 0.21%
59,563 $910,000
Q4 2020

Feb 03, 2021

BUY
$12.08 - $17.46 $211,436 - $305,602
17,503 Added 41.74%
59,437 $839,000
Q3 2020

Nov 04, 2020

SELL
$13.62 - $17.66 $39,157 - $50,772
-2,875 Reduced 6.42%
41,934 $657,000
Q2 2020

Aug 05, 2020

BUY
$13.04 - $23.23 $10,027 - $17,863
769 Added 1.75%
44,809 $785,000
Q1 2020

May 06, 2020

SELL
$11.52 - $26.46 $59,120 - $135,792
-5,132 Reduced 10.44%
44,040 $647,000
Q4 2019

Feb 07, 2020

BUY
$15.24 - $25.09 $14,554 - $23,960
955 Added 1.98%
49,172 $1.23 Million
Q3 2019

Nov 04, 2019

SELL
$14.91 - $25.01 $34,412 - $57,723
-2,308 Reduced 4.57%
48,217 $725,000
Q2 2019

Aug 07, 2019

BUY
$21.48 - $27.71 $1.09 Million - $1.4 Million
50,525 New
50,525 $1.26 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.41B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.